RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

Manzano et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d95b595e5bcb4e3b835bb1 — DOI: https://doi.org/10.1186/s12885-021-08078-y

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk <i>MYCN</i> -Not-Amplified Human Neuroblastoma· 2018 · 129 citations
2. Pembrolizumab as Neoadjuvant Therapy Preceding Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Group, Phase 2 Study· 2018 · 12 citations
3. GSVA: gene set variation analysis for microarray and RNA-Seq data· 2013 · 16,244 citations
4. A Molecular Taxonomy for Urothelial Carcinoma· 2012 · 993 citations
5. Biology and evolution of poorly differentiated neuroendocrine tumors· 2017 · 230 citations